Back
Cardiff Oncology 10K Form
Sell
43
CRDF
Cardiff Oncology
Last Price:
3.52
Seasonality Move:
5.49%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive CRDF News And Ratings
See the #1 stock for the next 7 days that we like better than CRDF
CRDF Financial Statistics
Sales & Book Value
| Annual Sales: | $488K |
|---|---|
| Cash Flow: | $-7.15M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.56 |
| Price / Book: | 2.26 |
Profitability
| EPS (TTM): | -0.93000 |
|---|---|
| Net Income (TTM): | $-41.44M |
| Gross Margin: | $240K |
| Return on Equity: | -47.42% |
| Return on Assets: | -42.26% |
Cardiff Oncology Earnings Forecast
Key Cardiff Oncology Financial Ratios
- The Gross Profit Margin over the past 10 years for CRDF is 98.11%.
- The Selling, General & Administrative Expenses for CRDF have been equal to 2,672.75% of Gross Profit Margin.
- The Research & Development expenses have been 6,732.99% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of CRDF is -8,492.01% of Total Revenues.
- Per Share Earnings over the last 14 years have been positive in 7 years.
Cardiff Oncology Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | CRDF |
| CUSIP: | 14147L |
| Website: | cardiffoncology.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 7.41 |
| Quick Ratio: | 7.19 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
CRDF Technical Analysis vs Fundamental Analysis
Sell
43
Cardiff Oncology (CRDF)
is a Sell
Is Cardiff Oncology a Buy or a Sell?
-
Cardiff Oncology stock is rated a Sell
The current Cardiff Oncology [CRDF] share price is $3.52. The Score for CRDF is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.